DOI:

Multifocal arterial fibromuscular dysplasia causing coronary artery dissection following coronary angiography

Jonas de Jong*, MD; Jan Piek, MD, PhD; Allard van der Wal, MD, PhD

A 31 year old man was referred to our hospital for evaluation of recurrent angina pectoris following recent inferior-posterior myocardial infarction. His previous medical history included a surgically corrected tetralogy of Fallot at four years of age. During coronary angiography of the left anterior descending artery, a dissection of the entire vessel developed (Figure 1).

Figure 1 and Movie 1. Acute dissection of the LAD during diagnostic catheterisation.

The dissection could not be crossed with a guidewire and the patient died.

Post mortem examination was performed. Histologically, the LAD dissection channel was filled with fresh haematoma indicating recent onset (Figure 2).

Figure 2. Cross section of the LAD showing a dissection channel in the outer part of the arterial media, filled with haematoma (Mallory’s stain).

The media showed abnormal presence of segmental ridges of medial tissue containing haphazardly arranged smooth muscle layers intermingled with elastin and collagenous tissue (Figure 3).

Figure 3. Detail of the coronary artery wall showing highly irregular medial ridges of fibromuscular tissue characteristic for the medial type of FMD. (Elastica van Gieson stain).

There were no signs of of inflammation (Figures 2 and 3) or previous dissections. These findings were diagnostic for the media type of fibromuscular dysplasia (FMD).

FMD is a segmental non-atherosclerotic non-inflammatory angiopathy of unknown aetiology. Renal and cervicocranial arteries are most commonly involved. Coronary FMD is very rare1. The disease is histologically classified according to the principal layer of arterial involvement (intimal-, medial- and peri-adventitial FMD). Medial FMD as found in our patient is by far (approximately 90% of cases) the commonest type.

Reference

Volume 5 Number 1
May 19, 2009
Volume 5 Number 1
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00601 Jun 15, 2026
Unloading the clock: when timing meets physiology in STEMI shock
Møller J and Schrage B
free

Editorial

10.4244/EIJ-D-26-00394 Jun 15, 2026
Transcatheter edge-to-edge repair for primary mitral regurgitation: what lies ahead?
Petronio A and Mazzola M
free

Original Research

10.4244/EIJ-D-25-01308 Jun 15, 2026
Temporal trends in mitral edge-to-edge repair for primary mitral regurgitation
Koell B et al

Flashlight

10.4244/EIJ-D-25-01353 Jun 15, 2026
Transcatheter approximation of papillary muscles
Tekieli L et al
open access

Editorial

10.4244/EIJ-D-26-00479 Jun 1, 2026
Valve thrombosis or valve deterioration: what truly drives the prognosis?
Waksman R and Phichaphop A
free
Trending articles
334.8

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
202.75

State-of-the-Art

10.4244/EIJ-D-21-00089 Jun 11, 2021
Intracoronary optical coherence tomography: state of the art and future directions
Ali ZA et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
32.2

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
27.6

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
27.6

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved